Last reviewed · How we verify
Pneumococcal pharyngitis — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Unasyn | AMPICILLIN | Bristol-Myers Squibb | Penicillin-class Antibacterial | Transient receptor potential cation channel subfamily M member 4 | 1965-01-01 | |
| Benzamycin | Erythromycin Lactobionate | Pfizer | Macrolide | Potassium voltage-gated channel subfamily H member 2 | 1964-01-01 | |
| E-Mycin | erythromycin | Generic (originally Abbott/Lilly) | Macrolide [EPC] | Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1 | 1952-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bristol-Myers Squibb · 1 drug in Pneumococcal pharyngitis
- Generic (originally Abbott/Lilly) · 1 drug in Pneumococcal pharyngitis
- Pfizer · 1 drug in Pneumococcal pharyngitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Pneumococcal pharyngitis:
- Pneumococcal pharyngitis treatment updates — RSS
- Pneumococcal pharyngitis treatment updates — Atom
- Pneumococcal pharyngitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Pneumococcal pharyngitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumococcal-pharyngitis. Accessed 2026-06-10.
Related
- Pneumococcal pharyngitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing